Shafer Michael D sold $15.3M of TMO

Shafer Michael D (Executive Vice President) sold 25,500 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $600.00 ($15.30M total) across 2 trades on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Shafer Michael D
Published Aug 13, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The newest disclosed fact is the size, price, and timing of the insider open-market sale under a pre-arranged 10b5-1 plan.

02

Market read

This provides a concrete, time-stamped insider selling datapoint for TMO, but it is pre-arranged and does not include new fundamentals.

03

What to watch

Traders may over-weight insider sales; the filing lacks context on total holdings, tax planning, or whether other executives are selling/buying around the same window.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-13, transaction dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Thermo Fisher Scientific, reported by an executive vice president.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

Thermo Fisher executive Michael D. Shafer sold $15.3M of TMO shares via a Rule 10b5-1 plan on 2026-08-11 at $600/share.

Expected impact

Likely limited, short-lived sentiment impact; follow-through depends on broader tape and any additional disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit Rule 10b5-1 pre-arrangement, reducing the signal of new negative information. The disclosed fact is time-stamped and tradable for positioning around sentiment, but it does not include earnings, guidance, or operational changes.

Market effects

No direct sector read-through; this is company-specific insider selling with no operational or regulatory trigger described.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a Rule 10b5-1 plan, it may reflect routine liquidity/compensation rather than bearish expectations.

Key entities

  • THERMO FISHER SCIENTIFIC INC.

    Subject of the Form 4 insider transaction disclosure.

  • Shafer Michael D

    Executive Vice President who sold 25,500 shares at $600/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TMOMed

Thermo Fisher Scientific Replenishes Buyback Capacity to $5 Billion

Thermo Fisher Scientific (TMO) authorized up to $5B in new stock repurchases, replacing a prior authorization with $1B remaining. The company spent $4B on buybacks in 2026's first nine months, with no purchases in Q3. Operating cash flow increased to $5.867B for the period, with $4.618B in free cash flow. The new authorization complements acquisitions, dividends, and debt obligations.